Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Extension Study to Evaluate the Safety and Tolerability of Daily Oral LUM-201 in Children With Growth Hormone Deficiency (GHD)

NCT07129759 is registered in ClinicalTrials.gov with Lumos Pharma as lead sponsor.

NCT NCT07129759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07129759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Extension Study to Evaluate the Safety and Tolerability of Daily Oral LUM-201 in Children With Growth Hormone Deficiency (GHD)
Lead sponsor
Lumos Pharma
Phase
Phase 3
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
February 28, 2030
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency (ghd)